RESUMEN

BACKGROUND: Exposure to blue light has been found to affect sleep. Reduced sleep has been found to affect academic performance. However, electronic gadget screen time, sleep quality and quantity and academic performance in undergraduate medical students has not been explored so far. The primary objective of this study was to explore Electronic Gadget Screen time, sleep quality, and sleep quantity and academic performance in Medical students. METHODS: The study was done in JSS Medical College, Mysuru. 400 students fromunder graduate course were selected through clustered random sampling. Data of electronic gadget usage was collected using a pre-tested proforma. Data of sleep quality, quantity was collected using Pittsburg Sleep Quality Index. Data of academic performance was collected from the marks sheet provided by the college authorities. RESULTS: Average screen time overall was 5.13 hours per day. On the whole, total Screen time does not have a direct relationship with sleep quantity or quality or academic performance. Rather than the total screen time, bed time gadget use seems to have a more significant relationship with academic performance. A non-significant relationship has been identified between screen time and quality of sleep with a p value= 0.2. Higher academic performance correlated with better sleep quality and better global PSQI scores. CONCLUSION: Bed time screen exposure plays a significant role in determining sleep quality, quantity and in turn academic performance.

Asunto(s)

RESUMEN

Abstract Background Impact of illness may vary with the medication adherence which in turn may vary with the attitude towards drugs. There is a paucity of research examining relationships between these variables. Objective To study the levels of drug attitude, adherence and its relationship with the impact of illness. Methods A total of 279 participants with mental illness in remission were assessed with socio-demographic and clinical proforma, scales like Hogan Drug Attitude Inventory (DAI), Impact of Illness Scale (IIS), and Morisky Medication Adherence Scale (MMAS) were used. Result Mean score on DAI, IIS, and MMAS were 2.38 (SD = 4.6), 25.88 (SD = 6.6), and 5.04 (SD = 2.2) respectively. On linear regression analysis (R2 = .122, DF = 2, F = 17.598, p < .001) IIS Score was statistically significant but negatively associated with the score of MMAS (p < .05) and DAI (p < .05). Discussion Impact of illness has an inverse relationship with the level of drug attitude and medication adherence. Improving drug attitude and adherence may buffer the impact of illness.

Asunto(s)

RESUMEN

INTRODUCTION: Conceptualization of depression may have bearing on treatment seeking. It may affect adherence behaviour of the patients. AIM: To find out the explanatory models and their relationship with socio-demographic variables and medication adherence in patients with depression. MATERIALS AND METHODS: Fifty-eight consecutive patients with depression in remission were recruited as per selection criteria. Socio-demographic details were collected. Patients were assessed using Mental Distress Explanatory Model Questionnaire (MDEMQ) and Morisky Medication Adherence Scale (MMAS). RESULTS: Significant scores were observed in all dimensions of explanatory models. In the Mann-Whitney U test the patient's marital status (MU=113.500, p=0.05, sig≤0.05, 2-tailed), and family history of mental illness (MU=165.5, p=0.03, sig≤0.05, 2-tailed) had a statistically significant group difference in the score of MDEMQ. In linear regression analysis, four predictors (MDEMQ subscales Stress, Western physiology, Non-Western physiology and Supernatural) had significantly predicted the value of MMAS (R2=0.937, f=153.558, p<0.001). CONCLUSION: Findings of this study suggested that patients with depression harbor multidimensional explanatory model. The levels of explanatory models are inversely associated with levels of medication adherence.

RESUMEN

Abstract Background Paranormal beliefs are common among patients with mental illness. Such beliefs may mediate conceptualization of illness, treatment satisfaction and medication adherence. Objective To study the level of paranormal beliefs and its relationship with explanatory models, treatment adherence and satisfaction using standardized assessment tool. Methods Eighty nine patients with mental illness in remission were assessed with Sociodemographic proforma, Revised Paranormal Belief Scale (RPBS), Mental Distress Explanatory Model Questionnaire (MMAS), Morisky Medication Adherence Scale (MMAS) and Short Assessment of Patient Satisfaction (SAPS). Results Results revealed a high level of paranormal beliefs on RPBS (Mean 83.96, SD ± 23.91). Variables that had a statistically significant group difference on the score of RPBS were domicile status (p < 05), diagnosis (p < 001), method of treatment sought before (p < 001). In a linear regression analysis four variables explained 35.4% of the variance (R2 = .38, R2Adjusted = .35, F = 13.04, p < .001) in RPBS Score. These variables were total score of MDEMQ (Beta = .308, t = 3.435, p < .001), total score of MMAS (beta = .357, t = 3. 716, p < .001) and magico-religious treatment received earlier (beta = .306, t = 3.52, p < .001) and SAPS. Discussion Based on the finding of this study, it may be concluded that the level of paranormal beliefs may vary with some demographic variables. Levels of paranormal beliefs is positively associated with explanatory models and adherence in patients with mental illness in remission.

RESUMEN

We are reporting a case of zolpidem induced multimodal hallucinations in a 22 year old female without any history of psychiatric disorders. Zolpidem, by acting on gamma-amino butyric acid type A receptor has a potential to cause a paradoxical reaction and there also exists a possibility of an induced delirium with its use. This case reports evaluates its potential to cause multimodal hallucinations. Zolpidem needs to be prescribed judiciously with the caution of potential side effects particularly in females.

Asunto(s)

RESUMEN

Atomoxetine, a selective norepinephrine inhibitor, is effective in comorbid anxiety and attention deficit hyperactivity disorder, however its role in panic disorder is unknown. We are presenting a case of panic disorder, who initially partially responded to clonazepam. When clonazepam was added with sertraline, escitalopram, desvenlafaxin, she did not improve significantly until paroxetine was added. When clonazepam-paroxetine combination was added with propranolol, etizolam, olanzepine, risperidone and amisulpride the symptom remission did not occur until a trial of Atomoxetine was done.

Asunto(s)